Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.
Location: United States, California, Emeryville
Employees: 11-50
Total raised: $110M
Founded date: 2017
Investors 13
Show more
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.04.2022 | Series B | $80M | - |
| 21.05.2020 | Series A | $30M | - |
Mentions in press and media 10
| Date | Title | Description |
| 22.04.2022 | Octant collects $80M Series B | Octant has raised an $80 million Series B led by Catalio Capital Management. The Emeryville, Calif.-based company is developing programmable biology and chemistry to create precision medicines for complex diseases, including rare genetic di... |
| 21.04.2022 | Who is Chris Dixon? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Considering that Chris Dixon, 50, is one of the most well-known venture capitalists in the indust... |
| 21.04.2022 | Octant Raises $80M in Series B Funding Round | Octant, an Emeryville, CA-based data-driven therapeutics company, raised $80M in Series B funding. The round was led by Catalio Capital Management with participation from Bristol Myers Squibb, Andreessen Horowitz Bio Fund, Allen & Co., ... |
| 21.04.2022 | Octant Secures $80M Series B Financing Round | EMERYVILLE, CA, Octant today announced an $80 million Series B financing round. >> Click here for more funding data on Octant >> To export Octant funding data to PDF and Excel, click here Octant, a next-generation, data-d... |
| 21.04.2022 | Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership | Data-driven therapeutics company Octant Bio is exploring new frontiers of drug development with $80 million in-pocket and a freshly signed Big Pharma partnership. Octant—a historical instrument used to navigate the oceans—is a fitting name ... |
| 21.05.2020 | Octant Raises $30M in Series A Financing | Octant, an Emeryville, Calif.-based synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases, raised $30m in Series A financing. The round was led by Andreessen Horowitz with par... |
| 20.05.2020 | Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery | Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuticals industry turns its attention to pre... |
| 20.05.2020 | Octant Launches with $30M Series A Financing | EMERYVILLE, CA, Octant has raised $30 million in a Series A financing led by venture capital firm Andreessen Horowitz. >> Click here for more funding data on Octant >> To export Octant funding data to PDF and Excel, click he... |
| - | BMS joins Octant’s $80M financing and signs on as a drug discovery partner | Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but the biotech is making progress and it ha... |
| - | Therapeutics Company Octant Secures $80 Million In Series B Funding | Octant recently announced it raised $80 million in funding. These are the details. Octant – a next-generation and data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseas... |